$591 Million is the total value of Bain Capital Life Sciences Investors, LLC's 11 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 10.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SWTX | SPRINGWORKS THERAPEUTICS INC | $196,595,000 | -29.9% | 7,281,307 | 0.0% | 33.25% | -20.5% | |
| ARQT | New | ARCUTIS BIOTHERAPEUTICS, INC. | $118,583,000 | – | 3,979,292 | +100.0% | 20.06% | – |
| DRNA | DICERNA PHARMACEUTICALS INC | $74,954,000 | -16.6% | 4,080,237 | 0.0% | 12.68% | -5.4% | |
| CNST | Sell | CONSTELLATION PHARMACEUTICALS INC. | $69,257,000 | -47.9% | 2,203,529 | -22.0% | 11.71% | -41.0% |
| DVAX | Buy | DYNAVAX TECHNOLOGIES CORP. | $30,819,000 | -36.3% | 8,730,707 | +3.3% | 5.21% | -27.7% |
| REPL | REPLIMUNE GROUP INC | $28,305,000 | -30.5% | 2,838,968 | 0.0% | 4.79% | -21.2% | |
| SVRA | SAVARA INC | $22,976,000 | 0.0% | 5,128,593 | 0.0% | 3.89% | +13.4% | |
| XFOR | X4 PHARMACEUTICALS INC | $16,485,000 | -6.5% | 1,648,485 | 0.0% | 2.79% | +6.0% | |
| MRNS | MARINUS PHARMACEUTICALS INC | $12,064,000 | -6.0% | 5,942,735 | 0.0% | 2.04% | +6.6% | |
| APTX | Buy | APTINYX INC | $12,006,000 | +57.8% | 5,558,425 | +149.8% | 2.03% | +78.9% |
| SLDB | SOLID BIOSCIENCES INC | $9,252,000 | -46.3% | 3,871,164 | 0.0% | 1.56% | -39.1% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, LP #2
- BC SW, LP #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.